Cost-Effectiveness Study of Three Antimalarial Drug Combinations in Tanzania

Simple item page
dc.contributor.authorMutabingwa, Theonest K.
dc.date.accessioned2020-02-25T06:35:20Z
dc.date.available2020-02-25T06:35:20Z
dc.date.issued2006
dc.description.abstractBackground As a result of rising levels of drug resistance to conventional monotherapy, the World Health Organization (WHO) and other international organisations have recommended that malaria endemic countries move to combination therapy, ideally with artemisinin-based combinations (ACTs). Cost is a major barrier to deployment. There is little evidence from field trials on the cost-effectiveness of these new combinations. Methods and Findings An economic evaluation of drug combinations was designed around a randomised effectiveness trial of combinations recommended by the WHO, used to treat Tanzanian children with non-severe slide-proven malaria. Drug combinations were: amodiaquine (AQ), AQ with sulfadoxine-pyrimethamine (AQ+SP), AQ with artesunate (AQ+AS), and artemether-lumefantrine (AL) in a six-dose regimen. Effectiveness was measured in terms of resource savings and cases of malaria averted (based on parasitological failure rates at days 14 and 28). All costs to providers and to patients and their families were estimated and uncertain variables were subjected to univariate sensitivity analysis. Incremental analysis comparing each combination to monotherapy (AQ) revealed that from a societal perspective AL was most cost-effective at day 14. At day 28 the difference between AL and AQ+AS was negligible; both resulted in a gross savings of approximately US$1.70 or a net saving of US$22.40 per case averted. Varying the accuracy of diagnosis and the subsistence wage rate used to value unpaid work had a significant effect on the number of cases averted and on programme costs, respectively, but this did not change the finding that AL and AQ+AS dominate monotherapy. Conclusions In an area of high drug resistance, there is evidence that AL and AQ+AS are the most cost-effective drugs despite being the most expensive, because they are significantly more effective than other options and therefore reduce the need for further treatment. This is not necessarily the case in parts of Africa where recrudescence following SP and AQ treatment (and their combination) is lower so that the relative advantage of ACTs is smaller, or where diagnostic services are not accurate and as a result much of the drug goes to those who do not have malaria.en_US
dc.identifier.citationWiseman, V., Kim, M., Mutabingwa, T.K. and Whitty, C.J., 2006. Cost-effectiveness study of three antimalarial drug combinations in Tanzania. PLoS Medicine, 3(10).en_US
dc.identifier.otherdoi: 10.1371/journal.pmed.0030373
dc.identifier.urihttp://hdl.handle.net/123456789/259
dc.language.isoenen_US
dc.publisherPLoS Medicine.en_US
dc.subjectThree Antimalarial Drug Combinationsen_US
dc.subjectTanzaniaen_US
dc.titleCost-Effectiveness Study of Three Antimalarial Drug Combinations in Tanzaniaen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Cost effectiveness study of 3 antimalarial drug combinations in Tz.PDF
Size:
107.07 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Journals

Total Collections: 1